›Reassess for xylazine or another non-opioid CNS depressant contribution instead
›Therapy-not-working troubleshooting
›Ventilation remains inadequate despite naloxone up to a reasonable cumulative dose
›Reconsider chest wall rigidity, airway obstruction, aspiration, or a non-opioid cause
›Move to bag valve mask ventilation and airway control rather than further naloxone escalation alone
›Ventilation adequate but sedation persists
›Xylazine or another non-opioid sedative most likely
›Manage supportively with airway monitoring and time, not additional naloxone
›Adverse effects management
›Acute opioid withdrawal precipitation
›Antiemetic therapy if vomiting
›Fluids for volume depletion
›Agitation
›Verbal de-escalation first
›If severe agitation threatens safety, short-acting sedative per local protocol with close respiratory monitoring given possible residual xylazine or opioid effect
Naloxone infusion protocol
›Indications
›Recurrent respiratory depression after an effective bolus
›Long-acting opioid, high-potency fentanyl analog, or nitazene exposure
›Infusion calculation
›Infusion rate as two-thirds of the effective bolus dose per hour
›Example effective bolus 1.5 mg total
›Infusion 1.0 mg/hour
›Bridging strategy
›Repeat bolus dose if respiratory depression recurs while the infusion is being established
›Titration and monitoring
›Titrate every 10 to 20 minutes to ventilation target
›Continuous pulse oximetry and capnography during infusion
›Observation after stopping infusion for renarcotization risk
›Minimum 6 to 12 hours of observation after the last naloxone dose for high-potency analog exposure, consistent with the disposition standard
Airway and ventilation management
›Ventilation support
›Bag valve mask ventilation
›Two-person technique with airway adjuncts as needed
›Chest wall rigidity management
›Naloxone IV 2 mg may partially reverse fentanyl-induced rigidity
›Often inadequate as sole treatment when bag valve mask ventilation remains ineffective
›Neuromuscular blockade for rapid sequence intubation when rigidity prevents ventilation
›Rocuronium IV 1.2 mg/kg
›Endotracheal intubation pathway
›Persistent apnea or refractory hypoventilation
›Inability to protect airway with aspiration risk
›Induction agent choice accounting for concurrent bradycardia and hypotension from possible xylazine effect
›Agents with less hemodynamic depression preferred when feasible
›Reversal-resistant sedation supportive care
›Lateral positioning and suction readiness for airway protection
›Serial reassessment of ventilation and mental status as separate parameters
›Avoidance of physical or chemical restraint that impairs ventilation or airway positioning
Hemodynamic support for xylazine-pattern bradycardia and hypotension
›Mechanism-directed approach
›Central alpha-2 agonism reducing sympathetic outflow, analogous to clonidine toxicity
›Bradycardia and hypotension often not primarily volume-mediated
›Distinguishing xylazine-pattern shock from other causes
›Bradycardia accompanying hypotension argues against pure hypovolemia or sepsis
›Bradycardia management
›Symptomatic bradycardia (heart rate less than 50/min with hypotension or altered perfusion)
›Atropine IV 0.5 mg
›Repeat every 3 to 5 minutes
›Maximum total dose 3 mg
›Reassessment of heart rate and blood pressure response after each atropine dose
›Hypotension management
›Initial crystalloid bolus
›500 to 1000 mL, reassess after each bolus
›Limited durable response expected given the central mechanism
›Refractory hypotension
›Norepinephrine infusion IV 0.05 to 0.5 mcg/kg/minute
›Titrate to mean arterial pressure target per local protocol
›Pure alpha-1 agonist avoided as first choice
›Phenylephrine may worsen reflex bradycardia in this setting
›Antidote status
›No antidote for xylazine approved for human use
›Atipamezole and yohimbine reverse xylazine in veterinary use
›Human dosing and safety not established; not for routine ED use outside toxicology consultation or a research protocol
›Supportive care and time as the management strategy
Wound care and infection management
›Wound assessment and initial care
›Irrigation and removal of grossly necrotic debris
›Local wound care per local protocol
›Moist wound dressing for non-infected wounds
›Pain control for wound care
›Acetaminophen PO/IV 650 to 1000 mg every 6 hours
›Maximum 3000 to 4000 mg/day per local protocol
›Opioid analgesia titrated cautiously to the patient's baseline tolerance
›Additive sedation risk with residual xylazine or opioid effect
›Higher analgesic requirement than an opioid-naive patient
›Antibiotic therapy
›Not indicated for uncomplicated, non-infected xylazine wounds
›Indicated for cellulitis, abscess, or systemic infection signs
›Ampicillin-sulbactam IV 3 g every 6 hours for polymicrobial coverage
›Vancomycin IV 15 to 20 mg/kg every 8 to 12 hours added for suspected MRSA
›Necrotizing soft tissue infection suspected
›Broad-spectrum empiric coverage
›Piperacillin-tazobactam IV 3.375 to 4.5 g every 6 to 8 hours
›Vancomycin IV 15 to 20 mg/kg every 8 to 12 hours
›Clindamycin IV 900 mg every 8 hours for toxin suppression
›Emergent surgical consultation for debridement
›Wound-specific precautions
›Contact precautions for draining wounds pending culture results
›Tetanus prophylaxis per immunization status
›Anticoagulation and fibrinolysis not indicated for xylazine wounds
›Mechanism is vasoconstriction and direct tissue injury, not thromboembolic occlusion
›Anticoagulation adds bleeding risk if debridement is planned
Withdrawal management beyond opioid agonist therapy
›Recognizing the combined withdrawal picture
›Standard opioid withdrawal features
›Mydriasis, diaphoresis, piloerection, myalgia, GI symptoms
›Additional features attributed to xylazine dependence in case reports
›Severe anxiety and dysphoria
›Autonomic instability including rebound hypertension and tachycardia
›Poor response to buprenorphine or methadone dosed by standard opioid withdrawal severity scores alone
›First-line opioid agonist therapy, unchanged from standard opioid withdrawal management
›Buprenorphine sublingual 2 to 4 mg initial dose, additional 2 to 8 mg based on symptoms
›Methadone 20 to 30 mg daily for withdrawal management when buprenorphine not feasible
›Adjuncts targeting the autonomic and dysphoric component
›Clonidine PO 0.1 mg every 6 to 8 hours
›Titration based on symptoms and blood pressure
›Held for hypotension or bradycardia per local protocol
›Dexmedetomidine infusion in a monitored setting for refractory autonomic symptoms and agitation
›IV 0.2 to 1.4 mcg/kg/hour, titrated
›Continuous cardiac and respiratory monitoring required given additive bradycardia and sedation risk
›Gabapentin PO 300 to 600 mg three times daily per local protocol as an adjunct for autonomic and anxiety symptoms
›Benzodiazepines reserved for severe agitation only
›Additive respiratory depression risk with residual opioid or xylazine effect
›Close respiratory monitoring required
›Emerging and unsettled practice
›No validated withdrawal management protocol specific to xylazine dependence
›Adjunct dosing above extrapolated from opioid and other alpha-2 agonist withdrawal literature and institutional case series
›Consensus guidance still evolving as of current practice
Iatrogenic harms of routine ED interventions
›Intubation
›Chest wall rigidity or difficult bag valve mask ventilation complicating laryngoscopy timing
›Induction agent selection accounting for baseline bradycardia and hypotension from possible xylazine effect
›Reflexive intubation for sedation alone avoidable if ventilation is already adequate; reassess before committing
›Sedation
›Additive CNS and respiratory depression when sedatives are given on top of unresolved opioid or xylazine effect
›Minimum effective dose for agitation or procedural needs, with continuous respiratory monitoring
›Fluid loading
›Limited benefit for xylazine-pattern hypotension given its central mechanism
›Pulmonary edema risk in a patient with impaired airway reflexes and aspiration risk
›Oxygen
›Supplemental oxygen can normalize SpO2 while hypoventilation and rising CO2 continue unrecognized
›Capnography needed to detect this masked deterioration
›Vasopressors
›Norepinephrine preferred over a pure alpha-1 agonist
›Phenylephrine risks worsening reflex bradycardia in a patient with central sympatholysis
›Mechanical circulatory support
›Intra-aortic balloon pump or other mechanical support not indicated for xylazine-pattern bradycardia and hypotension
›Refractory shock a prompt to reassess for an alternative or coingested cardiotoxic cause before mechanical support, since this toxidrome is expected to be reversible with supportive care
›Anticoagulation
›Not indicated for xylazine-associated wounds even when they appear ischemic
›Mechanism is vasoconstrictive and direct tissue injury, not thromboembolic
›Fibrinolysis
›Not indicated; xylazine wounds are not an arterial occlusive process
›Avoidance of a vascular occlusive workup driven by wound appearance alone
›Analgesia
›Undertreated pain risk if dosed as opioid-naive in a tolerant patient
›Additive sedation risk with residual xylazine or opioid effect favoring cautious titration and multimodal non-opioid analgesia first